HYQVIA is a liquid medicine that is given under the skin (subcutaneously) to treat primary immunodeficiency (PI) in adults.

Why HyQvia?

Once-a-month* infusions. Reliable infection protection.

HYQVIA offers once a month infusions and reliable infection protection.

*Every 3 or 4 weeks.

Less time spent infusing.
More time for daily activities.

Maximize your time between infusions with
HyQvia [Immune Globulin Infusion 10%
(Human) with Recombinant Human
Hyaluronidase], a monthly* subQ

Patients can wait up to 28 days between infusions.
Up to 28 days*
between infusions
Average infusion time is about 2 hours.
2 hour infusion
Average time for each
infusion was 2.08 hours
in the clinical trial

*Every 3 or 4 weeks.

Learn about how HyQvia was studied in clinical trials. Check out the trial details.

In the clinical trial, HyQvia provided reliable infection protection and the consistent Ig levels you expect from a subQ treatment.

HyQvia was studied in a clinical trial of 83 adults with PI with the main goal of measuring how many acute serious bacterial infections (ASBIs) they experienced over the course of 1 year. Keep scrolling to see efficacy results from the clinical trial.

ASBIs are short-term but serious infections caused by bacteria that require immediate medical care. The FDA standard for efficacy—that is, if an immunoglobulin works—is less than 1 ASBI per year. In the clinical trial, people taking HyQvia experienced significantly less than that.

In the clinical, trial patients taking once-monthly* HyQvia experienced:

ASBIs included 2 episodes of pneumonia.§

*Every 3 or 4 weeks.

The FDA standard for efficacy—that is, if an immunoglobulin works—is less than 1 ASBI per year. In the clinical trial, people taking HyQvia experienced significantly less than that (P< 0.0001).

§Both episodes of pneumonia were treated as outpatients with oral antibiotics. An additional episode of pneumonia requiring hospitalization occurred during the ramp-up.

Know you have the protection you deserve

In the clinical trial, patients taking HyQvia experienced an average of:

On average patients spend 0 days in hospitals per year due to infection while taking HYQVIA.
0 days
in hospitals per year
due to infection
On average patients missed 3.41 days of school and work due to infection while taking HYQVIA.
3.41
days
off work or school per
year due to infection

Experience a monthly* infusion with better systemic tolerability than IVIg

Systemic side effects affect the entire body and may occur within 72 hours, excluding infections. Local side effects occur at the infusion site.

The most common side effects observed in the clinical trial were: local side effects (pain, swelling, itching, and redness) and systemic side effects (headache, antibody formation against rHuPH20, fatigue, nausea, fever, and vomiting).

*Every 3 or 4 weeks.
Recombinant Human Hyaluronidase.

Rate of systemic side effects

0.20 rate of systemic
side effects per
HyQvia infusion
(222/1129)
0.42 rate of systemic
side effects per
IVIg infusion
(154/365)
52% Reduction in the rate
of systemic side effects
with HyQvia

Most common systemic side effects*

Rate = total number of systemic side effects divided by total number of infusions.

IVIg was administered for a median of 91 days and HYQVIA for a median of 42 days during the dose ramp-up period and 366 days during the efficacy period.

These systemic side effects occurred within 72 hours of infusion and/or were considered to be caused by the infusion.

*Excluding infections.

Learn about local side effects and tolerability

Local side effects like pain, swelling, itching, and redness occur at the infusion site and generally go away in a few hours. Local reactions are less likely after the first few infusions.

Rate of local side effects

0.21 rate of local
side effects per
HyQvia infusion
(234/1129)
0.01 rate of local
side effects per
IVIg infusion
(4/365)

~99%

of local side effects were considered mild to moderate.

70.5% were mild
(n=165)

Mild side effect causes temporary discomfort that goes away on its own, or with little medical intervention.

28.2% were
moderate
(n=66)

Moderate side effect causes a slight decline in function that goes away on its own, or with little medical intervention, and has no further consequences.

1% were
severe
(n=3)

Severe side effect results in impairment of function and can lead to temporary inability to resume normal lifestyle as it requires prolonged medical intervention and/or results in further consequences.

3 local severe reactions occurred during the clinical study: local infusion site pain, infusion site swelling, and infusion site swelling that extended from the abdominal infusion site to the genitalia.

Most common local side effects reported
in >1% of infusions

Most common side effects of HYQVIA were reported in >1% of infusions.

More time between infusions.
Focusing on planning her next trip.

Introducing Mary.

Mary is a thriving retiree and outdoor enthusiast who has been a HyQvia patient for years. Although she works closely with her doctor, she says PI treatment is just one part of her life. It doesn't define who she is.